Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Aug 20 · below the Ichimoku cloud · RSI 46 · MACD above its signal
None of the 29 investors followed here reported a position in OSRH in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a OSRH trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for OSRH.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.5 | -29.5 | 46.4 | 16.6 | -38.0 | -27.5 | 41.8 | -38.6 | -1.8 | -22.2 | −62.8% | ||
| 2025 | -1.6 | -73.2 | -38.2 | -28.2 | 7.4 | -4.8 | -50.1 | 12.9 | -31.1 | 26.7 | 9.7 | -24.2 | −95.1% |
| 2024 | 0.9 | 0.4 | 0.2 | 0.7 | 0.0 | 0.3 | 0.7 | -0.1 | 0.6 | 1.5 | 1.1 | 3.2 | +9.8% |
| 2023 | 0.1 | 0.7 | 0.7 | 0.5 | 0.5 | 0.4 | 0.7 | -0.2 | 0.5 | +4.0% |
Buy / hold / sell counts
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. The company was formerly known as OSR Holdings, Inc. and changed its name to OSR Health, Inc. in June 2026. OSR Health, Inc. was incorporated in 2020 and is based in Bellevue, Washington.